drugset / Trial / NCT01613482

TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention

NCT01613482

Phase 3 Terminated 13 enrolled Centre Oscar Lambret
RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluate the survival without metastasis in patients treated by Trastuzumab in association with other chemotherapies for a breast cancer expressing HER2-NEU.

Timeline

Start
2008-01
Primary completion
2009-08
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Background Trastuzumab Monoclonal antibody 2 mg/kg